MedPath

KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

A study involving 508 stage III colon cancer patients from the CALGB 89803 trial found that KRAS mutational status does not significantly influence disease-free or overall survival, regardless of adjuvant chemotherapy regimen.

Introduction

KRAS mutations are common in colorectal cancer, with approximately 30-40% of colon cancers harboring mutations in codons 12 and 13 of KRAS. While KRAS mutation in metastatic colorectal cancer predicts resistance to anti-EGFR targeted therapy, its prognostic role in colon cancer independent of anti-EGFR therapy has been controversial.

Methods

This study analyzed 508 cases from 1264 patients with stage III colon cancer enrolled in the CALGB 89803 trial, which compared adjuvant chemotherapy regimens of 5-fluorouracil and leucovorin with or without irinotecan. KRAS mutations were detected in 178 tumors (35%) using Pyrosequencing. The study assessed the prognostic significance of KRAS mutation, adjusting for potential confounders such as age, sex, tumor location, and microsatellite instability (MSI) status.

Results

Patients with KRAS-mutated tumors did not experience any significant difference in disease-free survival (DFS), recurrence-free survival (RFS), or overall survival (OS) compared to those with KRAS-wild-type tumors. Five-year DFS, RFS, and OS rates were similar between the two groups. The effect of KRAS mutation on survival did not significantly differ based on clinical features, chemotherapy arm, or MSI status.

Discussion

The findings suggest that KRAS mutational status does not have a substantial prognostic or predictive role in stage III colon cancer treated with adjuvant chemotherapy. This is consistent with most previous large studies on colon cancers, indicating that while KRAS mutation is a critical biomarker for predicting response to anti-EGFR therapy in metastatic colorectal cancer, it does not significantly predict patient prognosis in stage III colon cancer.

Conclusion

In conclusion, KRAS mutational status did not significantly predict clinical outcome in this study of stage III colon cancer patients. Although KRAS mutational testing is crucial for assessing the appropriateness of anti-EGFR therapy in advanced colorectal cancer, KRAS status is unlikely to meaningfully predict patient prognosis in stage III colon cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Novel KRAS-Targeting Agents Show Promise in Clinical Trials for Advanced Cancers

Roswell Park Comprehensive Cancer Center is conducting clinical trials for new KRAS-targeting agents that offer alternative approaches to treating KRAS-mutated cancers.
One trial involves an agent that directly breaks down the KRAS molecule, effectively cutting off the signal for cell growth in cancers with the G12D mutation.

NRG258 Trial: Chemoradiation Fails to Improve Overall Survival in Advanced Endometrial Cancer

Long-term follow-up of the NRG258 phase III trial reveals no significant difference in overall survival between adjuvant chemoradiation and chemotherapy alone for locally advanced endometrial carcinoma.
The study, involving 736 patients, showed that chemoradiation did not improve recurrence-free survival compared to chemotherapy alone, despite reducing local recurrence rates.

Bayer Initiates Phase I Trial of SOS1 Inhibitor BAY3498264 for Advanced KRAS-Mutated Tumors

Bayer has commenced a Phase I clinical trial to evaluate the safety and efficacy of BAY3498264, a novel oral SOS1 inhibitor, in patients with advanced KRAS G12C-mutated solid tumors.
The study aims to assess BAY3498264's potential in treating various KRAS-mutated cancers, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer, by targeting the MAPK signaling pathway.

Phase 3 IMAGINE Trial of Clazakizumab in Kidney Transplant Rejection Fails to Meet Primary Endpoint

The Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with chronic active antibody-mediated rejection (caAMR), did not meet its primary efficacy outcome.
An interim analysis led to early termination of the trial, revealing no significant difference in estimated glomerular filtration rate (eGFR) between the clazakizumab and placebo groups at week 52.

KRAS Mutation Subtypes Linked to Varying Outcomes in Pancreatic Cancer

A multicenter study reveals that specific KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) correlate with different survival outcomes.
The KRAS-G12D mutation is associated with more aggressive cancer and poorer prognosis, while KRAS-G12V and KRAS-G12R mutations show better overall survival.

ctDNA Analysis Predicts Survival and Treatment Response in Colorectal Cancer

ctDNA positivity post-surgery strongly predicts recurrence and poorer overall survival in CRC patients, outperforming traditional risk factors.
ctDNA monitoring identifies patients who benefit from adjuvant chemotherapy (ACT), with MRD-positive patients showing significant improvement.

Cyramza Plus Lonsurf Fails to Improve Overall Survival in Metastatic Colorectal Cancer

The phase 3 IKF-AIO-RAMTAS trial showed that adding Cyramza to Lonsurf did not significantly improve overall survival in heavily pretreated metastatic colorectal cancer patients.
Subgroup analysis revealed potential benefits in female patients and those with left-sided tumors, who experienced improved survival outcomes with the Cyramza/Lonsurf combination.

Significant Improvement in Progression-Free Survival with SARCLISA Combination Therapy for Previously Treated Multiple Myeloma

A Phase 3 trial reveals that patients with previously treated multiple myeloma who stopped responding to Revlimid experienced a median progression-free survival of 41.7 months with SARCLISA combined with Kyprolis and dexamethasone, compared to 20.8 months with Kyprolis and dexamethasone alone.

Cetuximab Enhances Treatment Efficacy for Metastatic Colorectal Cancer with KRAS Wild-Type

Adding cetuximab to the FOLFIRI regimen significantly improves outcomes for metastatic colorectal cancer patients with KRAS wild-type, including overall survival, progression-free survival, and response rates.

Reference News

[1]
KRAS Mutation in Stage III Colon Cancer and Clinical ...
pmc.ncbi.nlm.nih.gov · Nov 24, 2009

In a study of 508 stage III colon cancer patients, KRAS mutation status did not significantly affect disease-free, recur...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy